Sino BiologicalInc. (301047.SZ) stock: key figures, P/E, revenue and dividend

Health Care · Biotechnology · China

Price
106.06 CNY
Market cap
12.90 bn CNY
P/E (2025)
87.32
P/S (2025)
18.44
Dividend yield
2.07 %
Net margin
21.12 %
Return on equity (ROE)
2.78 %
Return on assets (ROA)
2.67 %

Sino BiologicalInc. financials

Fiscal year20242025
Revenue613.67 m CNY699.56 m CNY
Gross profit449.76 m CNY512.71 m CNY
Operating income54.72 m CNY104.42 m CNY
EBIT145.31 m CNY182.63 m CNY
Net income121.93 m CNY147.74 m CNY
Diluted EPS – continuing operations1.00 CNY1.21 CNY

Full history since 2019, charts and your own formulas

This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.

Sign up for freeOpen interactive view

About Sino BiologicalInc.

Sino Biological,Inc. engages in the provision of recombinant protein and antibody reagents for life science researchers in China and internationally. The company offers recombinant proteins, antibodies, cDNA clones, kits, serum-free media, protein modification, qPCR primers, cell lysates, and purification reagents. It also provides comprehensive solutions, including autoimmune disease research, kinase drug discovery, cytokine and growth factor, SARS-CoV-2 variants research, comprehensive CAR-T therapy, 3D organoids research, ADC development, influenza vaccine development, and multispecific antibody development solutions, as well as solutions for MSCs therapy and in vitro efficacy evaluation. It serves academic research institutions, biotech companies, and pharmaceutical companies. Sino Biological,Inc. was founded in 2016 and is headquartered in Beijing, China.

More stocks

All stocks →

Not investment advice. All data without warranty, price as of 06.11.2026. Details in the risk notice.